RE:CAR-T update Caribou is focused on an internal pipeline led by allogeneic CAR-T cell therapies against CD19 and BCMA. Both candidates are in the clinic and could provide an off-the-shelf alternative to existing cell therapies such as Gilead’s Yescarta and Johnson & Johnson’s Carvykti.
Pfizer stepped up to help fund the pipeline in July, investing $25 million in Caribou. The biotech earmarked the cash for clinical development of its allogeneic anti-BCMA CAR-T cell therapy, dubbed CB-011.
https://www.fiercebiotech.com/biotech/abbvie-axes-caribou-car-t-deal-continuing-cascade-punted-cancer-pacts
Pfizer is backing Caribou Biosciences with a $25 million equity investment, money the genome editing company will pour into its allogeneic CAR-T cell therapy for multiple myeloma.
Durability is a widespread issue for allogeneic CAR-T developers. In an attempt to tackle CAR-T cell exhaustion and maintain high anti-tumor activity for a longer time, Caribou had removed the PD-1 receptors from its anti-CD19 candidate CB-010.
https://www.fiercebiotech.com/biotech/pfizer-pours-25m-equity-investment-caribous-cell-therapies